Company Overview and News

 
Killam Apartment REIT Announces October 2018 Distribution

2018-10-17 globenewswire
HALIFAX, Nova Scotia, Oct. 17, 2018 (GLOBE NEWSWIRE) -- Killam Apartment REIT (TSX: KMP.UN) is pleased to announce its October 2018 monthly distribution. The distribution of $0.05333 per unit will be paid on November 15, 2018, to unitholders of record on October 31, 2018.
KMP KMP.UN

 
Killam Apartment REIT Further Diversifies Its Assets Base With $88 Million in Acquisitions

2018-10-01 globenewswire
HALIFAX, Nova Scotia, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Killam Apartment REIT (TSX: KMP.UN) ("Killam") is pleased to announce $88 million in new acquisitions, including $82.1 million in newly constructed apartments and $5.7 million in land to expand its development pipeline. The acquisitions include properties in Calgary, Ottawa, Charlottetown and Waterloo.
KMP KMP.UN

 
Killam Apartment REIT Announces Timing of Third Quarter 2018 Results and Conference Call

2018-10-01 globenewswire
HALIFAX, Nova Scotia, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Killam Apartment REIT (TSX: KMP.UN) will be releasing its financial results for the third quarter ended September 30, 2018, on Wednesday, November 7, 2018, after the market closes. A webcast and conference call to discuss these results and current business initiatives will be held on Thursday, November 8, 2018, at 10:00 AM eastern time.
KMP KMP.UN

 
Killam Apartment REIT Announces September 2018 Distribution

2018-09-18 globenewswire
HALIFAX, Nova Scotia, Sept. 18, 2018 (GLOBE NEWSWIRE) -- Killam Apartment REIT (TSX: KMP.UN) is pleased to announce its September 2018 monthly distribution. The distribution of $0.05333 per unit will be paid on October 15, 2018, to unitholders of record on September 28, 2018.
KMP KMP.UN

1
Northview Apartment REIT: Valuation And Development Program Support Positive Outlook

2018-08-23 seekingalpha
Multi-family residential REITs are one of the best inflation hedges and one of the best hedges against rising interest rates.
CDPYF KMP.UN NVU.UN MFC 0945 NTR CCJ MFC BIP BEAV CWSRF BEP

 
Killam Apartment REIT Announces August 2018 Distribution

2018-08-16 globenewswire
HALIFAX, Nova Scotia, Aug. 16, 2018 (GLOBE NEWSWIRE) -- Killam Apartment REIT (TSX: KMP.UN) is pleased to announce its August 2018 monthly distribution. The distribution of $0.05333 per unit will be paid on September 17, 2018, to unitholders of record on August 31, 2018.
KMP KMP.UN

 
Killam's (KMPPF) CEO Philip Fraser on Q2 2018 Results - Earnings Call Transcript

2018-08-12 seekingalpha
Good morning, ladies and gentlemen, and welcome to the Killam Apartment REIT Second Quarter 2018 Financial Results Conference Call. [Operator Instructions]. Please note that this call is being recorded today, August 9, 2018 at 9:00 A.M. Eastern Time.
KMP.UN LB

 
Northview: Ontario Will Become Its Primary Growth Driver

2018-08-09 seekingalpha
Demand for residential rental properties in Ontario is expected to remain at a high level in the next decade.
CDPYF NPRUF KMP.UN NVU.UN

 
Killam Apartment REIT Reports Q2-2018 Results, Including Strong Operating Performance, Historic Low Debt Levels and $51 Million of Acquisitions

2018-08-08 globenewswire
HALIFAX, Nova Scotia, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Killam Apartment REIT (TSX: KMP.UN) ("Killam") today reported its results for the three and six months ended June 30, 2018.
KMP KMP.UN

 
Killam Apartment REIT Announces July 2018 Distribution

2018-07-18 globenewswire
HALIFAX, Nova Scotia, July 18, 2018 (GLOBE NEWSWIRE) -- Killam Apartment REIT (TSX:KMP.UN) is pleased to announce its July 2018 monthly distribution. The distribution of $0.05333 per unit will be paid on August 15, 2018, to unitholders of record on July 31, 2018.
KMP KMP.UN

 
Killam Apartment REIT Announces Timing of Second Quarter 2018 Results and Conference Call

2018-07-12 globenewswire
HALIFAX, Nova Scotia, July 12, 2018 (GLOBE NEWSWIRE) -- Killam Apartment REIT (TSX:KMP.UN) will be releasing its financial results for the second quarter ended June 30, 2018, on Wednesday, August 8, 2018, after the market closes. A webcast and conference call to discuss these results and current business initiatives will be held on Thursday, August 9, 2018, at 9:00 AM eastern time.
KMP KMP.UN

 
Killam Apartment REIT Closes $57.5 Million Public Offering of Trust Units

2018-06-26 globenewswire
NOT FOR DISTRIBUTION TO THE UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
KMP KMP.UN

 
Killam Apartment REIT Announces June 2018 Distribution

2018-06-18 globenewswire
HALIFAX, Nova Scotia, June 18, 2018 (GLOBE NEWSWIRE) -- Killam Apartment REIT (TSX:KMP.UN) is pleased to announce its June 2018 monthly distribution. The distribution of $0.05333 per unit will be paid on July 16, 2018, to unitholders of record on June 29, 2018.
KMP KMP.UN

 
Northview Apartment REIT: Will Its Growth Momentum Continue In 2018?

2018-06-18 seekingalpha
The REIT should be able to carry its growth momentum thanks to its robust development pipeline, its value creation initiatives, and strong economic growth in Canada.
CDPYF NPRUF KMP.UN NVU.UN

 
Killam Apartment REIT Announces $50 Million Public Offering of Trust Units

2018-06-06 globenewswire
NOT FOR DISTRIBUTION TO THE UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
KMP KMP.UN

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...